Acute intraperitoneal infection with a hypervirulent Acinetobacter baumannii isolate in mice.
Acinetobacter Infections
/ microbiology
Acinetobacter baumannii
/ isolation & purification
Acute Disease
Animals
Bacterial Load
Chemokines
/ metabolism
Host-Pathogen Interactions
Inflammation
/ pathology
Inflammation Mediators
/ metabolism
Kinetics
Macrophage Activation
Mice, Inbred BALB C
Mice, Inbred C57BL
Microbial Viability
Peritoneal Cavity
/ microbiology
Virulence
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 04 2019
25 04 2019
Historique:
received:
24
01
2019
accepted:
09
04
2019
entrez:
27
4
2019
pubmed:
27
4
2019
medline:
8
10
2020
Statut:
epublish
Résumé
Acinetobacter baumannii infection has become a major cause of healthcare-associated infection and a critical pathogen in the WHO antimicrobial resistance research and development priority list. Catheter-related septicemia is one of the major clinical manifestations of A. baumannii infection associated with high morbidity and mortality. In this study, we used a clinical A. baumannii strain (LAC-4) that is hypervirulent to immunocompetent C57BL/6 and BALB/c mice and established a mouse model of intraperitoneal (i.p.) A. baumannii infection. Our study showed that i.p. LAC-4 infection of C57BL/6 and BALB/c mice induces a lethal or sublethal infection with high bacterial burdens in peritoneal cavity, blood and tissues and the infected mice either succumbed to the infection within 24 hours or completely recovered from the infection. The infection induces acute peritoneal recruitment of neutrophils and other innate immune cells, and the local and systemic production of proinflammatory cytokines and chemokines (IL-1β, IL-5, IL-6, TNF-α, RANTES, MIP-1β, MCP-1, KC and IL-10). Mechanistic studies suggest an important role of macrophages in the host innate defense in this model in that in vitro stimulation of peritoneal macrophages with killed LAC-4 induced a similar pattern of cytokine/chemokine responses to those in the infected mice, and depletion of peritoneal macrophages rendered the mice significantly more susceptible to the infection. Thus, this mouse infection model will provide an alternative and useful tool for future pathogenesis studies of A. baumannii-associated septicemia and identification and characterization of important virulence factors, as well as serve as a surrogate model for rapid evaluation of novel therapeutics and vaccines for this emerging infectious agent.
Identifiants
pubmed: 31024025
doi: 10.1038/s41598-019-43000-4
pii: 10.1038/s41598-019-43000-4
pmc: PMC6484084
doi:
Substances chimiques
Chemokines
0
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6538Références
Microbes Infect. 2009 Oct;11(12):946-55
pubmed: 19573619
J Antimicrob Chemother. 2012 Jun;67(6):1439-45
pubmed: 22389456
Virulence. 2013 Aug 15;4(6):467-72
pubmed: 23863607
New Microbiol. 2015 Jan;38(1):67-73
pubmed: 25742149
Clin Microbiol Infect. 2007 Feb;13(2):196-198
pubmed: 17328733
Sci Rep. 2015 Mar 02;5:8643
pubmed: 25728466
Viruses. 2015 Mar 13;7(3):1189-217
pubmed: 25781919
Biopolymers. 2011;96(2):126-9
pubmed: 20564029
J Infect Dis. 2015 Apr 15;211(8):1296-305
pubmed: 25378635
J Infect Dis. 2011 Feb 15;203(4):545-8
pubmed: 21216865
Antimicrob Agents Chemother. 2013 Aug;57(8):3601-13
pubmed: 23689726
J Infect Dis. 2017 Feb 15;215(suppl_1):S52-S57
pubmed: 28375520
Infect Immun. 2009 Mar;77(3):1015-21
pubmed: 19103777
Clin Infect Dis. 2006 Mar 1;42(5):692-9
pubmed: 16447117
Clin Microbiol Rev. 2008 Jul;21(3):538-82
pubmed: 18625687
Clin Microbiol Infect. 2005 Nov;11(11):868-73
pubmed: 16216100
Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1391-8
pubmed: 21479973
Infect Immun. 2007 Dec;75(12):5597-608
pubmed: 17908807
Infect Immun. 2011 Aug;79(8):3317-27
pubmed: 21576323
BMC Microbiol. 2008 Dec 10;8:216
pubmed: 19068136
mBio. 2014 May 27;5(3):e01076-14
pubmed: 24865555
Front Immunol. 2015 May 19;6:225
pubmed: 26042120
Infect Immun. 2011 Jan;79(1):518-26
pubmed: 20974823
Vaccine. 2011 Aug 5;29(34):5705-10
pubmed: 21679737
Front Cell Infect Microbiol. 2017 May 04;7:156
pubmed: 28523249
Front Immunol. 2017 Apr 12;8:441
pubmed: 28446911
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30297362
J Clin Microbiol. 2008 Aug;46(8):2499-507
pubmed: 18524965
Curr Protoc Microbiol. 2017 Aug 11;46:6G.3.1-6G.3.23
pubmed: 28800159
FEMS Microbiol Rev. 2013 Mar;37(2):130-55
pubmed: 22568581
Diagn Microbiol Infect Dis. 2016 Dec;86(4):392-398
pubmed: 27712928
J Infect. 2010 Feb;60(2):154-61
pubmed: 19748521
J Clin Microbiol. 2005 Apr;43(4):1632-9
pubmed: 15814977
J Immunol. 2010 May 15;184(10):5791-801
pubmed: 20393138
Infect Immun. 2012 Feb;80(2):651-6
pubmed: 22104104
J Neuroimmune Pharmacol. 2011 Dec;6(4):551-65
pubmed: 21826405
Antimicrob Agents Chemother. 1997 Feb;41(2):345-51
pubmed: 9021190
Infect Immun. 2012 Oct;80(10):3381-8
pubmed: 22825448
Infect Immun. 2014 Sep;82(9):3910-8
pubmed: 25001601
Infect Immun. 2008 Aug;76(8):3577-86
pubmed: 18541654
PLoS One. 2012;7(6):e40019
pubmed: 22768201